Lexaria Bioscience Corp. announced on October 9, 2024, that dosing has begun for human pilot study #3. This study is investigating a DehydraTECH-processed version of tirzepatide, derived from Zepbound®, in an oral dose format.
The study is being conducted in up to 10 healthy volunteers, marking a significant step in the clinical development of Lexaria's proprietary technology. This trial aims to evaluate the performance of an oral GLP-1/GIP drug candidate.
Initiating human dosing is a critical milestone, moving the company closer to gathering essential data on the safety and efficacy of its oral drug delivery platform for a prominent GLP-1 drug.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.